THE INTERRELATION BETWEEN THE LEVEL OFTHE BIOMARKER FABP4 AND THE RISK OF DEVELOPING TYPE 2 DIABETES

Objective: to estimate the level of the biomarker of endothelial dysfunction FABP4 and to study its interrelation with the risk of developing DM type 2. Materials and methods: the cross-sectional trial was conducted among 389 respondents in the East Kazakhstan region, from 18 to 65 years old. The risk of developing DM type 2 was assessed using the FINDRISK scale. The serum level of the FABP4 biomarker was determined by multiplexing investigation an immunofluorescence method using XMap technology. Results and discussion: in assessment the risk of DM type 2, distinguished groups of patients with a low risk of developing DM type 2 included 310 (80%) participants, and a high group of risk of DM type 2- 79 (20%). The level of the biomarker FABP4 significantly prevailed in the group with high risk of the developing DM type 2 in comparison with the low group of risk. A positive direct correlation (r-0.59) was found, statistically significant, indicated the level of the FABP4 marker is increasing with an increase the risk of developing DM type 2. Conclusions: The results of the research identified groups of patients with different risk of developing DM type 2, detected an increased level of the FABP4 biomarker in the high group of risk of DM type 2, and established the interrelation between the increased level of this biomarker of endothelial dysfunction FABP4 and the increased risk of developing DM type 2.

FINDRISK, biomarker FABP4, risk of diabetes, FINDRISK, endothelial dysfunction, FABP4 биомаркері, FINDRISK

1. Всемирная организация здравоохранения. Информационный бюллетень. Диабет. Ноябрь 2016. [Электронный ресурс]. - Режим доступа: http://www.who.int/mediacentre/factsheets/fs312/ru/

2. Мельникова Ю. С. Эндотелиальная дисфункция как центральное звено патогенеза хронических болезней /Ю. С. Мельникова, Т. П. Макарова //Казанский медицинский журнал. - 2015. - Т. 96, №4. - С. 659-660.

3. Национальный регистр Республики Казахстан за 2016 год. [Электронный ресурс]. -Режим доступа: http://www.parlam.kz/ru/bloas/ ferho/Details/4/20136

4. Оценка десятилетнего риска развития сахарного диабета 2 типа в Карагандинской области: популяционное кросс-секционное исследование /Д. Н. Шерьязданова, Е. М. Ларюшина, А. А. Турмухамбетова, Л. Г. Тургунова // Медицина и экология. - 2016. -№2. - С. 64-68.

5. Abduelkarem A. R. Risk calculation of developing type 2 diabetes in Libyan adults /A. R. Abduelkarem, S. I. Sharif, A. M. Hammrouni // Pract. Diab. Int. - 2009. - V. 26. - Рp. 148-151.

6. Aimin X. Adipocyte Fatty Acid-Binding Protein Is a Plasma Biomarker Closely Associated with Obesity and Metabolic Syndrome /X. Aimin, Y. Wang, J. Xu //Clinical Chemistry. - 2006. -№52, V. 3. - Рp. 405-413.

7. Alssema M. Finnish questionnaire reasonably good predictor of the incidence of diabetes in The Netherlands /M. Alssema, E. J. Feskens, S. J. Bakker //Ned. Tijdschr. Geneeskd. - 2008. -№1. - Т. 152 (44). - Рp. 2418-2424.

8. Annete W. K. Serum Adipocyte Fatty Acid -Binding Protein as a New Biomarker Predicting the Development of Type 2 Diabetes /W. K. Annete, X. Aimin, C. Pak //Diabetes Care. - 2007. -№30. - Pp. 2667-2672.

9. Chow W. S. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study /W. S. Chow, A.W. Tso, A. Xu, M. M. Yuen //J. Am. Heart. Assoc. 2013. - №2. - Рp. 2-6.

10. Daousi C. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors /C. Daousi, I. F. Casson, G. V. Gill, I. A. MacFarlane //Postgrad. Med. J. -2006. - №82 (966). - Рp. 280-284.

11. Djousse L. Plasma Fatty Acid-Binding Protein 4, Nonesterified Fatty Acids, and Incident Diabetes in Older Adults /L. Djousse, O. Khawaja, M. Bartz //Diabetes care. - 2012. - №35 (8). -Рp. 1701-1707.

12. Djoussea L. Plasma levels of FABP4, but not FABP3, are associated with increased risk of diabetes /L. Djoussea, J. M. Gazianoa //Lipids. -2012. - №47 (8). - Рp. 757-762.

13. Haffner S. M. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome /S. M. Haffner, L. Mykkanen, R. A. Valdez //J. Clin. Endocrinol. Metab. - 1994. - V. 79. - Pp. 1806-1810.

14. Jeffrey B. Combined Adipocyte-Macrophage Fatty Acid-Binding Protein Deficiency Improves Metabolism, Atherosclerosis, and Survival in Apolipoprotein E-Deficient Mice /B. Jeffrey, M. Kazuhisa //Circulation. - 2004. - №14. -Рp. 1492-1498.

15. Mohieldein A. H. Risk estimation of type 2 Diabetes and dietary habits among adult nondiabetics in central Saudi Arabia /A. Mohieldein, H. H. Mohieldein, M. Alzohairy //GJHS. - 2009. - V. 3.- Рp. 123-133.

16. Mohieldein A. H. Diabetes risk in a Cuban primary care setting in persons with no known glucose abnormalities /A. Mohieldein, A. A. Naranjo, A. Y. Rodriguez //MEDICC. - 2013. - V. 15. - Рp. 16-19.

17. Ota H. Elevation of Fatty Acid-Binding Protein 4 Is Predisposed by Family History of Hypertension and Contributes to Blood Pressure Elevation /H. Ota, M. Furuhashi, S. Ishimura // American Journal of hypertension. - 2012. - V. 25, №10. - Pp. 1124-1130.

18. Reaven G. M. Role of insulin resistance in human disease //Diabetes. - 1998. - V. 37. -Pp.1595-1607.